Scientists test Next-Gen flu shot using mRNA tech
NCT ID NCT06125691
Summary
This was the first human study of a new seasonal flu vaccine called ARCT-2138, which uses self-amplifying mRNA technology. It tested the vaccine's safety and ability to trigger an immune response in 139 healthy younger and older adults. The study compared different doses of the new vaccine to standard, already-approved flu shots.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emeritus Research Camberwell
Melbourne, Victoria, 3124, Australia
-
Nucleus Network Brisbane Clinic
Brisbane, Queensland, Australia
Conditions
Explore the condition pages connected to this study.